siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies?

Abstract

Acute viral respiratory tract infections (AVRIs) are a major burden on human health and global economy and amongst the top five causes of death worldwide resulting in an estimated 3.9 million lives lost every year. In addition, new emerging respiratory viruses regularly cause outbreaks such as SARS‐CoV‐1 in 2003, the "Swine flu" in 2009, or most importantly the ongoing SARS‐CoV‐2 pandemic, which intensely impact global health, social life, and economy. Despite the prevalence of AVRIs and an urgent need, no vaccines—except for influenza—or effective treatments were available at the beginning of the COVID‐19 pandemic. However, the innate RNAi pathway offers the ability to develop nucleic acid‐based antiviral drugs. siRNA sequences against conserved, essential regions of the viral genome can prevent viral replication. In addition, viral infection can be averted prophylactically by silencing host genes essential for host–viral interactions. Unfortunately, delivering siRNAs to their target cells and intracellular site of action remains the principle hurdle toward their therapeutic use. Currently, siRNA formulations and chemical modifications are evaluated for their delivery. This progress report discusses the selection of antiviral siRNA sequences, delivery techniques to the infection sites, and provides an overview of antiviral siRNAs against respiratory viruses.

Non-Woven Infection Prevention Fabrics Coated with Biobased Cranberry Extracts Inactivate Enveloped Viruses Such as SARS-CoV-2 and Multidrug-Resistant Bacteria

“…SARS-CoV-2 is a highly pathogenic enveloped positive-sense single-stranded RNA virus [ 13 , 14 , 15 ] that belongs to the Baltimore group IV [ 16 ]. This global life-threatening situation needs the development of new antimicrobial approaches that could treat or prevent COVID-19 infections [ 17 , 18 , 19 , 20 , 21 , 22 ]. In this regard, non-woven fabrics are currently used for the fabrication of infection prevention clothing such as face masks, caps, scrubs, shirts, trousers, disposable gowns, overalls, hoods, aprons, and shoe covers.…”

Pulmonary surfactant as a versatile biomaterial to fight COVID-19

“…Secondly, besides improving the extracellular availability of various therapeutics in the lung, PS has the newfound potential to promote the intracellular delivery of membrane-impermeable drugs. In particular, inhalation therapy with small interfering RNA (siRNA) is a promising approach to address acute respiratory viral infections, both by targeting viral proteins responsible for infectivity or replication, as well as host-related proteins that play a crucial role in viral infection or disease severity [ 41 , 42 ]. To be functional, siRNA molecules require cytosolic delivery in the target cell of interest, for which they are typically encapsulated into nanoparticles ( i.e.…”

3D Printed Cobalt-Chromium-Molybdenum Porous Superalloy with Superior Antiviral Activity

“…SARS-CoV-2 is a highly pathogenic enveloped positive-sense single-stranded RNA virus [ 13 , 14 , 15 ] that belongs to the Baltimore group IV [ 16 ]. This global life-threatening situation needs the development of new antimicrobial approaches that could treat or prevent COVID-19 infections [ 17 , 18 , 19 , 20 , 21 , 22 ]. In this regard, non-woven fabrics are currently used for the fabrication of infection prevention clothing, such as face masks, caps, scrubs, shirts, trousers, disposable gowns, overalls, hoods, aprons, and shoe covers.…”